company background image
ISKJ

Human Stem Cells InstituteMISX:ISKJ Stock Report

Last Price

₽104.15

Market Cap

₽7.5b

7D

-9.9%

1Y

160.4%

Updated

19 Jan, 2022

Data

Company Financials
ISKJ fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance1/6
Financial Health2/6
Dividends0/6

ISKJ Stock Overview

Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia.

Price History & Performance

Summary of all time highs, changes and price drops for Human Stem Cells Institute
Historical stock prices
Current Share Price₽104.15
52 Week High₽177.00
52 Week Low₽33.35
Beta1.16
1 Month Change-15.29%
3 Month Change21.44%
1 Year Change160.38%
3 Year Change1,101.27%
5 Year Change491.76%
Change since IPO610.49%

Recent News & Updates

May 09
Risks To Shareholder Returns Are Elevated At These Prices For Public Joint-Stock Company "Human Stem Cells Institute" (MCX:ISKJ)

Risks To Shareholder Returns Are Elevated At These Prices For Public Joint-Stock Company "Human Stem Cells Institute" (MCX:ISKJ)

When close to half the companies in Russia have price-to-earnings ratios (or "P/E's") below 10x, you may consider...

Shareholder Returns

ISKJRU BiotechsRU Market
7D-9.9%-4.1%-5.3%
1Y160.4%-19.9%11.1%

Return vs Industry: ISKJ exceeded the Russian Biotechs industry which returned -19.3% over the past year.

Return vs Market: ISKJ exceeded the Russian Market which returned 6.1% over the past year.

Price Volatility

Is ISKJ's price volatile compared to industry and market?
ISKJ volatility
ISKJ Average Weekly Movement15.5%
Biotechs Industry Average Movement7.5%
Market Average Movement4.9%
10% most volatile stocks in RU Market8.9%
10% least volatile stocks in RU Market3.1%

Stable Share Price: ISKJ is more volatile than 90% of Russian stocks over the past 3 months, typically moving +/- 16% a week.

Volatility Over Time: ISKJ's weekly volatility has increased from 10% to 16% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003n/aPrikhodko Viktorovichhttps://hsci.ru

Public Joint-Stock Company ‘Human Stem Cells Institute’ operates as a biotech company primarily in Russia. The company engages in the drug discovery, research and development, and marketing of proprietary products and services in the field of regenerative medicine; bio-insurance; medical genetics, including reproductive genetics; gene therapy; and biopharmaceutics. It owns and operates Gemabank, a family cord blood stem cell bank in Russia and the CIS; and Reprobank, a reproductive cell and tissue bank for personal storage of reproductive cells and tissues, as well as a sperm/oocyte donation.

Human Stem Cells Institute Fundamentals Summary

How do Human Stem Cells Institute's earnings and revenue compare to its market cap?
ISKJ fundamental statistics
Market Cap₽7.50b
Earnings (TTM)₽20.13m
Revenue (TTM)₽1.19b

372.5x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ISKJ income statement (TTM)
Revenue₽1.19b
Cost of Revenue₽545.65m
Gross Profit₽641.97m
Expenses₽621.85m
Earnings₽20.13m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.28
Gross Margin54.06%
Net Profit Margin1.69%
Debt/Equity Ratio77.2%

How did ISKJ perform over the long term?

See historical performance and comparison

Valuation

Is Human Stem Cells Institute undervalued compared to its fair value and its price relative to the market?

41.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ISKJ (RUB104.15) is trading below our estimate of fair value (RUB177.12)

Significantly Below Fair Value: ISKJ is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ISKJ is poor value based on its PE Ratio (372.5x) compared to the European Biotechs industry average (27.9x).

PE vs Market: ISKJ is poor value based on its PE Ratio (372.5x) compared to the Russian market (7.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ISKJ's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ISKJ is overvalued based on its PB Ratio (33.6x) compared to the XE Biotechs industry average (3.9x).


Future Growth

How is Human Stem Cells Institute forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Human Stem Cells Institute has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Human Stem Cells Institute performed over the past 5 years?

64.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ISKJ has a large one-off loss of RUB23.8M impacting its June 30 2021 financial results.

Growing Profit Margin: ISKJ's current net profit margins (1.7%) are lower than last year (11.7%).


Past Earnings Growth Analysis

Earnings Trend: ISKJ has become profitable over the past 5 years, growing earnings by 64.9% per year.

Accelerating Growth: ISKJ's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: ISKJ had negative earnings growth (-80.9%) over the past year, making it difficult to compare to the Biotechs industry average (50.7%).


Return on Equity

High ROE: ISKJ's Return on Equity (8.2%) is considered low.


Financial Health

How is Human Stem Cells Institute's financial position?


Financial Position Analysis

Short Term Liabilities: ISKJ's short term assets (RUB531.0M) exceed its short term liabilities (RUB403.0M).

Long Term Liabilities: ISKJ's short term assets (RUB531.0M) do not cover its long term liabilities (RUB646.0M).


Debt to Equity History and Analysis

Debt Level: ISKJ's net debt to equity ratio (66.3%) is considered high.

Reducing Debt: ISKJ's debt to equity ratio has increased from 26% to 77.2% over the past 5 years.

Debt Coverage: ISKJ's debt is well covered by operating cash flow (50.9%).

Interest Coverage: ISKJ's interest payments on its debt are not well covered by EBIT (3x coverage).


Balance Sheet


Dividend

What is Human Stem Cells Institute current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ISKJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ISKJ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISKJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISKJ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: ISKJ is not paying a notable dividend for the Russian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ISKJ's dividend in 3 years as they are not forecast to pay a notable one for the Russian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Prikhodko Viktorovich (62 yo)

no data

Tenure

Mr. Prikhodko Alexander Viktorovich, Ph D., served as Chairman of the Board of Public Joint-Stock Company "Human Stem Cells Institute" since July 30, 2012 until October 2020 and serves as its General Direc...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Public Joint-Stock Company "Human Stem Cells Institute"'s employee growth, exchange listings and data sources


Key Information

  • Name: Public Joint-Stock Company "Human Stem Cells Institute"
  • Ticker: ISKJ
  • Exchange: MISX
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₽7.498b
  • Shares outstanding: 71.99m
  • Website: https://hsci.ru

Location

  • Public Joint-Stock Company "Human Stem Cells Institute"
  • 18/1 Olimpiysky prospect
  • Moscow
  • 129110
  • Russia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/01/19 21:18
End of Day Share Price2022/01/19 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.